Natera, Inc. (NTRA)

Market Cap	21.37B
Revenue (ttm)	1.53B
Net Income (ttm)	-214.69M
Shares Out	132.02M
EPS (ttm)	-1.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,760,007
Open	154.68
Previous Close	158.09
Day's Range	154.01 - 163.05
52-Week Range	58.53 - 175.63
Beta	1.64
Analysts	Strong Buy
Price Target	152.67 (-5.69%)
Earnings Date	Nov 12, 2024

About NTRA

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplanta...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 2, 2015
• Employees: 3,293
• Stock Exchange: NASDAQ
• Ticker Symbol: NTRA
• Website: https://www.natera.com

Financial Performance

In 2023, Natera's revenue was $1.08 billion, an increase of 31.99% compared to the previous year's $820.22 million. Losses were -$434.80 million, -20.63% less than in 2022.

Analyst Forecast

According to 15 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price forecast is $152.67, which is a decrease of -5.69% from the latest price.

Price Target

$152.67

(-5.69% downside)

Analyst Consensus: Strong Buy